U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag™ (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma

On March 18, 2022

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219

Related Post

Chubb Life Appoints Jack Chang to Lead Newly Acquired Life Insurance Operations of Cigna in Taiwan

Chubb Life Appoints Jee Eun Cho to Lead LINA, its Newly Acquired Life Insurance Operations of Cigna in Korea

Chubb Life Announces Gail Costa Will Lead Newly Acquired Life Insurance Operations of Cigna in New Zealand